Related Experiment Video
Updated: May 11, 2026

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
[Surgical treatment for hypertrophic obstructive cardiomyopathy: a report of 118 cases]
Ming-yao Luo1, Shui-yun Wang, Yun-hu Song
1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.
Insights
Transaortic extended septal myectomy is a safe and effective surgical treatment for hypertrophic obstructive cardiomyopathy (HOCM), significantly relieving left ventricular outflow tract (LVOT) obstruction and improving patient symptoms and survival.
Area of Science:
- Cardiovascular Surgery
- Cardiology
- Thoracic Surgery
Context:
- Hypertrophic obstructive cardiomyopathy (HOCM) presents a significant clinical challenge.
- Left ventricular outflow tract (LVOT) obstruction is a primary cause of symptoms and morbidity in HOCM patients.
- Surgical intervention, specifically septal myectomy, is a key treatment modality.
Purpose:
- To evaluate the clinical outcomes, including early and midterm survival, of transaortic extended septal myectomy in patients with HOCM.
- To assess the efficacy of the extended Morrow's procedure in relieving LVOT obstruction and improving functional status.
- To analyze the safety profile and complication rates associated with the surgical procedure.
Summary:
- A retrospective analysis of 118 consecutive HOCM patients undergoing transaortic extended septal myectomy (Morrow's procedure) was conducted.
- The procedure demonstrated a low in-hospital mortality (0.8%) and significant reductions in LVOT gradient and New York Heart Association (NYHA) class.
- Midterm follow-up revealed no deaths or readmissions, with all patients experiencing improved physical ability and sustained NYHA class I-II.
Impact:
- Transaortic extended septal myectomy offers a safe and highly efficacious treatment option for HOCM.
- The surgical intervention effectively alleviates LVOT obstruction, leading to substantial symptomatic improvement and enhanced quality of life.
- This procedure contributes to favorable early and midterm survival rates in patients with hypertrophic obstructive cardiomyopathy.
Objective:
To assess the clinical outcomes of transaortic extended septal myectomy on early and midterm survival of patients with hypertrophic obstructive cardiomyopathy (HOCM).
Methods:
From October 2009 to April 2012, 118 consecutive patients underwent extended Morrow's procedure for HOCM. There were 69 males and 49 females with an average age of (46 ± 13) years. Their clinical data were analyzed retrospectively. Preoperative transthoracic, intraoperative transoesophageal and postoperative transthoracic echocardiography was performed to assess septal thickness, left ventricular outflow tract (LVOT) gradient, mitral valve function and systolic anterior motion (SAM) of anterior mitral valve leaflet, etc. Concomitant surgical procedures were performed if other cardiac diseases required surgical interventions. Follow-up study was carried out during subsequent clinic visits at outpatient department and through telephone interviews with patients and their relatives.
Results:
The septal thickness was (25 ± 7) mm. SAM was detected in all. The in-hospital mortality was 0.8% (1/118) since one patient died of multiple organs failure one week later. Postoperative echocardiography demonstrated marked reduction in LVOT gradient (92 ± 22 vs 13 ± 10 mm Hg (1 mm Hg = 0.133 kPa), P = 0.000), New York Heart Association (NYHA) class (2.9 ± 0.6 vs 1.2 ± 0.4, P = 0.000) and significant improvement in mitral regurgitation. Concomitant surgical procedures were performed in 45 cases (38.1%, all for preexisting conditions). Complications included complete atrioventricular block (n = 3), first degree atrioventricular block (n = 6), complete left bundle branch block (n = 51), intraventricular conduction delay or left anterior division block (n = 26), transient renal dysfunction (n = 2) and intra-aortic-balloon-pumping (n = 2). No other severe complication was observed. During a follow-up period of 1 - 27 (7 ± 6) months, there was no readmission or death. All patients reported significant increase in physical ability and obvious decrease in limiting symptoms. At the latest follow-up, the NYHA functional class maintained grade I-II in all. And mitral regurgitation remained absent or mild.
Conclusion:
Surgical procedure for HOCM patients is both safe and efficacious. It provides an excellent relief of LVOT obstruction.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
